Constitutive activation of 5-lipoxygenase in the lungs of patients with idiopathic pulmonary fibrosis.
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Idiopathic pulmonary fibrosis (IPF) is a progressive disorder characterized by inflammation, fibroblast proliferation, and accumulation of extracellular matrix proteins. Leukotrienes (LTs) are pro-inflammatory and pro-fibrogenic mediators derived from the 5-lipoxygenase (5-LO) pathway of arachidonic acid metabolism. They are thought to play a role in a number of disease processes, but have received relatively little attention in investigations into the pathogenesis of IPF. In this study, we measured the levels of immunoreactive LTs B(4) and C(4) in homogenates of lung tissue obtained from patients with newly diagnosed, untreated IPF, as compared to levels measured in homogenates of uninvolved nonfibrotic lung tissue from patients undergoing resectional surgery for bronchogenic carcinoma. Compared to homogenates on nonfibrotic control lung, homogenates from IPF patients contained 15-fold more LTB(4) and 5-fold more LTC(4). IPF homogenate levels of LTB(4) were significantly correlated with histologic indices of both inflammation (r=0.861) and fibrosis (r=0.926). Activation of 5-LO is known from in vitro studies to be associated with localization of the enzyme at the nuclear membrane. Immunohistochemical staining for 5-LO protein in alveolar macrophages (AMs) demonstrated that such an "activated" localization pattern was significantly more frequent in IPF lung (19.2+/-3.3% of cells) than in control lung (9.3+/-0.9%); this localization pattern was rarely seen (3.2%) in sections from a truly normal transplant donor lung. Consistent with these data, AMs obtained from IPF patients by bronchoalveolar lavage, purified by adherence, and cultured in the absence of a stimulus for 16 h elaborated significantly greater amounts of LTB(4) and LTC(4) than did control AMs obtained from normal volunteers. These data indicate that the 5-LO pathway is constitutively activated in the lungs of patients with IPF, and the AM represents at least one cellular source of LT overproduction in this disorder. We speculate that LTs participate in the pathogenesis of IPF, and their overproduction in this disorder may be amenable to specific pharmacotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lewis (1990) · doi:10.1056/nejm199009063231006 · Cited by 1,200
Carré, P. C., Mortenson, R. L., King, T. E., Noble, P. W., Sable, C. L., & Riches, D. W. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115501 · Cited by 253 · cited 2×
“Alternatively, it is possible that cytokines such as interleukin-8, also reported to be increased in the lower respiratory tract of patients with IPF (9, 10), could stimulate or prime AMs for enhanced LT synthesis (34).”
Bitterman, P. B., Wewers, M. D., Rennard, S. I., Adelberg, S., & Crystal, R. G. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112364 · Cited by 232 · cited 1×
“The growth-promoting actions of LTs on lung fibroblasts are enhanced when endogenous fibroblast production of prostaglandin E2, which itself suppresses cell proliferation (55, 56), is pharmacologically inhibited (52); in this regard, we have recently reported (57) that fibroblasts isolated from the lungs of patients w…”
Cited by
Matute-Bello, G., Downey, G., Moore, B. B., Groshong, S. D., Matthay, M. A., Slutsky, A. S., & Kuebler, W. M. (2011) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2009-0210st · Cited by 1,988
Integrating mechanisms of pulmonary fibrosis
Wynn, T. A. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20110551 · Cited by 1,274
Mechanisms of Pulmonary Fibrosis
Thannickal, V. J., Toews, G. B., White, E. S., Lynch III, J. P., & Martinez, F. J. (2004) · Annual Review of Medicine · doi:10.1146/annurev.med.55.091902.103810 · Cited by 808
Targeting metabolic dysregulation for fibrosis therapy
Zhao, X., Kwan, J. Y. Y., Yip, K., Liu, P. P., & Liu, F.-F. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0040-5 · Cited by 513
A Role for Cysteinyl Leukotrienes in Airway Remodeling in a Mouse Asthma Model
HENDERSON, W. R., TANG, L.-O., CHU, S.-J., TSAO, S.-M., CHIANG, G. K. S., JONES, F., JONAS, M., PAE, C., WANG, H., & CHI, E. Y. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.1.2105051 · Cited by 418
Inflammation and cancer: how friendly is the relationship for cancer patients?
Aggarwal, B. B., & Gehlot, P. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2009.06.020 · Cited by 405
Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodeling
Holgate, S. T., Peters-Golden, M., Panettieri, R. A., & Henderson, W. R. (2003) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2003.25 · Cited by 318
Self-citationFunk, C. D. (1996) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/s0005-2760(96)00107-5 · Cited by 265
Disorders of lung matrix remodeling
Chapman, H. A. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420729 · Cited by 224
Bronchiolitis Obliterans After Allogeneic Hematopoietic Stem Cell Transplantation
Williams, K. M. (2009) · JAMA · doi:10.1001/jama.2009.1018 · Cited by 217
Chien, J. W., Duncan, S., Williams, K. M., & Pavletic, S. Z. (2010) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2009.11.002 · Cited by 205
“[84,85] Human and murine studies have demonstrated high levels of leukotrienes with BOS after lung transplant and pulmonary fibrosis[86–88] and a pilot study with montelukast (a leukotriene inhibitor) showed benefit in 3 of 5 patients with BOS after HCT[85].”
A pivotal role of cytosolic phospholipase A2 in bleomycin-induced pulmonary fibrosis
Nagase, T., Uozumi, N., Ishii, S., Kita, Y., Yamamoto, H., Ohga, E., Ouchi, Y., & Shimizu, T. (2002) · Nature Medicine · doi:10.1038/nm0502-480 · Cited by 163
Hepcidin expression and iron transport in alveolar macrophages
Nguyen, N.-B., Callaghan, K. D., Ghio, A. J., Haile, D. J., & Yang, F. (2006) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00484.2005 · Cited by 143
“They appear to play a critical role in the pathogenesis of numerous pulmonary diseases, including chronic obstructive pulmonary disease (11), idiopathic pulmonary fibrosis (30, 41), asthma (5), and pulmonary sarcoidosis (6, 28).”
Background
Metadata
- Authors
- Wilborn, J., Bailie, M., Coffey, M., Burdick, M., Strieter, R., & Peters-Golden, M.
- Venue
- Journal of Clinical Investigation
- Published
- 1996-04-15
- Volume
- 97
- Issue
- 8
- Pages
- 1827-1836
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2055962814
- Cited by
- 176
- References
- 3
- FWCI
- 6.89
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.